HARP Stock Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Harpoon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$6.20 |
| 52 Week Low | US$0.59 |
| Beta | 1.35 |
| 1 Month Change | 36.00% |
| 3 Month Change | 27.48% |
| 1 Year Change | -78.25% |
| 3 Year Change | -93.15% |
| 5 Year Change | n/a |
| Change since IPO | -92.44% |
Recent News & Updates
Recent updates
Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30
Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04We're Not Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn
May 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Mar 16Harpoon Therapeutics (NASDAQ:HARP) Shareholders Booked A 37% Gain In The Last Year
Mar 10Could The Harpoon Therapeutics, Inc. (NASDAQ:HARP) Ownership Structure Tell Us Something Useful?
Feb 03
Harpoon Therapeutics' HPN217 an orphan drug in U.S. for multiple myeloma
Jan 13Harpoon Therapeutics -2.6%, proposes public offering
Jan 06Harpoon Therapeutics: Potential For Explosive Growth
Jan 03Have Insiders Been Buying Harpoon Therapeutics, Inc. (NASDAQ:HARP) Shares This Year?
Dec 30Harpoon Therapeutics reports partial response from HPN424 early-stage study in prostate cancer
Dec 08Shareholder Returns
| HARP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.6% | -0.8% | 1.7% |
| 1Y | -78.3% | 4.4% | -9.6% |
Return vs Industry: HARP underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: HARP underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| HARP volatility | |
|---|---|
| HARP Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HARP is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: HARP's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 86 | Julie Eastland | https://www.harpoontx.com |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications.
Harpoon Therapeutics, Inc. Fundamentals Summary
| HARP fundamental statistics | |
|---|---|
| Market Cap | US$33.89m |
| Earnings (TTM) | -US$70.86m |
| Revenue (TTM) | US$32.15m |
1.1x
P/S Ratio-0.5x
P/E RatioIs HARP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HARP income statement (TTM) | |
|---|---|
| Revenue | US$32.15m |
| Cost of Revenue | US$72.37m |
| Gross Profit | -US$40.22m |
| Other Expenses | US$30.65m |
| Earnings | -US$70.86m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | -125.09% |
| Net Profit Margin | -220.41% |
| Debt/Equity Ratio | 0% |
How did HARP perform over the long term?
See historical performance and comparison